Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Maxim transfers coverage of Cardiff Oncology at buy; PT $20

Maxim Group transferred coverage of Cardiff Oncology (NASDAQ:CRDF) to analyst Naureen Quibria, Ph.D., with a “buy” rating and $20 price target. The stock closed at $5.76 on Aug. 6. Cardiff’s PLK inhibitor, onvansertib...

August 9, 2021

Markets

HCW ups BeyondSpring to buy from neutral; PT $100

H.C. Wainwright upgraded BeyondSpring (NASDAQ:BYSI) to “buy” from “neutral” with a price target of $100 after the company reported positive topline results from its DUBLIN-3 registrational trial of plinabulin in...

August 4, 2021

Markets

Ladenburg starts Immutep at buy; PT $8.30

Ladenburg Thalmann launched coverage of Immutep of Australia (NASDAQ:IMMP) with a “buy” rating and $8.30. The stock closed at $3.46 0n Aug. 2. Immutep is a clinical-stage immuno-oncology company focused on developing...

August 3, 2021

Markets

111 Inc. named to top 10 leaders of China’s new pharma retail industry

111 Inc. (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, was named as one of the top 10 leaders of China’s new...

July 30, 2021

Markets

BTIG cuts Misonix to neutral on proposed acquisition by Bioventus

BTIG downgraded Misonix (NASDAQ:MSON) to “neutral” on a pending acquisition by Bioventus. Under the accord, Misonix shareholders would receive either 1.6839 shares of Bioventus common stock or $28 for each share held...

July 30, 2021

Markets

Cantor halves Ardelyx PT to $7 from $14; maintains OW rating

Cantor Fitzgerald slashed its price target for Ardelyx (NASDAQ:ARDX) to $7 from $14 after the company received a complete response letter from the FDA for its NDA for tenapanor to control serum phosphorus in adult...

July 30, 2021

Markets

Cantor starts Nyxoah at OW; PT $43

Cantor Fitzgerald initiated coverage of Nyxoah SA (NASDAQ:NYXH) with an “overweight” rating and 12-month price target of $43, citing the company’s “pipeline and uniquely differentiated product”. The stock closed at $32...

July 28, 2021

Markets

Canaccord starts CVRx at buy; PT $30

Canaccord Genuity initiated coverage of CVRx (NASDAQ:CVRX) with a “buy” rating and price target of $30. The stock closed at $20.22 on July 23. “We believe that CVRx is uniquely positioned in addressing significant unmet...

July 26, 2021

Markets

Stifel starts Acumen Pharma at buy; PT $27

Stifel launched coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $27 price target. The stock closed at $17.08 on July 23. Acumen is a biotechnology company focused on the development of a next...

July 26, 2021

Markets

Cantor starts SELLAS Life Sciences at OW; PT $18

Cantor Fitzgerald launched coverage of SELLAS Life Sciences (NASDAQ:SLS) with an “outperform” rating and $18 price target. The stock closed at $8.60 on July 20. SELLAS is a late-stage immune-oncology company that is...

July 21, 2021

Markets

Stifel starts GH Research at buy; PT $26

Stifel launched coverage of GH Research PLC (NASDAQ:GHRS) with a “buy” rating and price target of $26. The stock closed at $17.25 on July 19. “We believe GH offers an attractive way to invest in the psychedelics space...

July 20, 2021

Markets

Analysts start Alpha Teknova at outperform, buy

Analysts for William Blair and BTIG initiated coverage of Alpha Teknova (NASDAQ:TKNO) with “outperform” and “buy” ratings, respectively, citing the company’s exposure to several large, rapidly growing markets. “In...

July 20, 2021

Markets

SVB Leerink starts Elevation Oncology at OP; PT $20

SVB Leerink launched coverage of Elevation Oncology (NASDAQ:ELEV) with an “outperform” rating and $20 price target. The stock closed at $12.10 on July 19. Elevation is a clinical development-stage biotech company...

July 20, 2021

Markets

WB starts Talkspace at outperform

William Blair launched coverage of Talkspace (NASDAQ:TALK) with an “outperform” rating, pointing to the company’s platform and significant market opportunity. The stock closed at $5.81 on July 16. “We believe the...

July 19, 2021

Markets

Maxim transfers coverage of Immutep at buy; PT $8

Maxim Group transferred primary coverage of Immutep (NASDAQ:IMMP) to analyst, Naureen Quibria, Ph.D., with a “buy” rating and $8 price target. The stock closed at $3.53 on July 15. Immutep has a pipeline of...

July 16, 2021

Markets

Canaccord ups Acutus Medical to buy from hold; PT to $18 from $11

Canaccord Capital upgraded Acutus Medical (NASDAQ:AFIB) to “buy” from “hold” and raised its price target to $18 from $11, citing the company’s pre-announcement of second quarter results, which “illustrate early signs of...

July 15, 2021

Markets

Cantor starts Novan at OW; PT $30

Cantor Fitzgerald initiated coverage of Novan (NASDAQ:NOVN) with an “overweight” rating and $30 price target. The stock closed at $9.10 on July 8. Novan is a clinical-stage biotechnology company focused on leveraging...

July 9, 2021

Markets

SVB Leerink starts F-Star Therapeutics at OP; PT $39

SVB Leerink launched coverage of F-Star Therapeutics (NASDAQ:FSTX) with an “outperform” rating and $39 price target. The stock closed at $7.34 on July 7. F-star’s pipeline generates drug candidates that work with...

July 8, 2021

Markets

Stifel ups ChemoCentryx to buy; PT $31

Stifel upgraded ChemoCentryx (NASDAQ:CCXI) to “buy” from “hold” and raised its price target to $31 from $26, citing a more favorable risk/reward for avacopan heading into a new PDUFA date. The stock closed at $14.05 on...

July 7, 2021

Markets

Cantor starts Jaguar Health at OW; PT $5

Cantor Fitzgerald initiated coverage of Jaguar Health (NASDAQ:JAGX) with an “overweight” rating and price target of $5. The stock closed at $1.49 on July 6. Jaguar Health is a commercial-stage pharmaceuticals company...

July 7, 2021

Markets

HCW starts Axcella Health at buy; PT $14

H.C. Wainwright initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $14 price target. The stock closed at $3.97 on July 2. Axcella Health is a clinical-stage biotechnology company pioneering a new...

July 6, 2021

Markets

Cantor starts Arcturus Therapeutics at OW; PT $71

Cantor Fitzgerald launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with an “overweight” rating and $71 price target. The stock closed at $35.94 on July 1. Arcturus is leveraging its proprietary lipid-based...

July 2, 2021

Subscribe